<DOC>
	<DOC>NCT01833169</DOC>
	<brief_summary>The purpose of this signal seeking study is to determine whether treatment with BKM120 demonstrates sufficient efficacy in select pathway-activated solid tumors and/or hematologic malignancies to warrant further study.</brief_summary>
	<brief_title>BKM120 for Patients With PI3K-activated Tumors</brief_title>
	<detailed_description />
	<criteria>Patient has a confirmed diagnosis of a solid tumor or hematological malignancy with the exception of endometrial cancer, glioblastoma, nonsmall cell lung cancer, prostate cancer or breast cancer. Patient's tumor has been evaluated and preidentified to have activation of the PI3K pathway, at a CLIA certified laboratory Patient must have received at least one prior treatment for recurrent metastatic and /or locally advanced disease and for whom no standard therapy options are anticipated to result in a durable remission. Patient must have progressive and measurable disease as per RECIST 1.1. or other appropriate hematological guidelines Patient has an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1 Patient has received previous treatment with BKM120 Patient has symptomatic CNS metastases Patient has mood disorder as outlined in Section 5 Patient has received chemotherapy or other anticancer therapy ≤ 4 weeks (6 weeks for nitrosourea, antibodies or mitomycinC) prior to starting study drug.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Solid tumor</keyword>
	<keyword>malignancy</keyword>
	<keyword>hematologi malignancy</keyword>
	<keyword>PI3K pathway activation</keyword>
	<keyword>BKM120</keyword>
	<keyword>signature</keyword>
	<keyword>AML, acute myelogenous leukemia</keyword>
	<keyword>cervical, ovarian</keyword>
	<keyword>hepatobiliary</keyword>
	<keyword>buparlisib</keyword>
</DOC>